Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice


Colon cancer is one of the best-understood neoplasms from a genetic perspective1,2,3, yet it remains the second most common cause of cancer-related death, indicating that some of its cancer cells are not eradicated by current therapies4,5. What has yet to be established is whether every colon cancer cell possesses the potential to initiate and sustain tumour growth, or whether the tumour is hierarchically organized so that only a subset of cells—cancer stem cells—possess such potential6,7. Here we use renal capsule transplantation in immunodeficient NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). Purification experiments established that all CC-ICs were CD133+; the CD133- cells that comprised the majority of the tumour were unable to initiate tumour growth. We calculated by limiting dilution analysis that there was one CC-IC in 5.7 × 104 unfractionated tumour cells, whereas there was one CC-IC in 262 CD133+ cells, representing >200-fold enrichment. CC-ICs within the CD133+ population were able to maintain themselves as well as differentiate and re-establish tumour heterogeneity upon serial transplantation. The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem cells.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Xenografts generated from both bulk and CD133 + colon cancer cells resemble the original patient tumour.
Figure 2: Expression of CD133 in tumour and normal colonic tissue.


  1. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal cancer tumorigenesis. Cell 61, 759–767 (1990)

    Article  CAS  Google Scholar 

  2. Fearon, E. R. & Jones, P. A. Progressing toward a molecular description of colorectal cancer development. FASEB J. 6, 2783–2790 (1992)

    Article  CAS  Google Scholar 

  3. Radtke, F. & Clevers, H. Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904–1909 (2005)

    Article  CAS  ADS  Google Scholar 

  4. Nelson, H. et al. Guidelines 2000 for colon and rectal cancer surgery. J. Natl Cancer Inst. 93, 583–596 (2001)

    Article  CAS  Google Scholar 

  5. O'Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96, 1420–1425 (2004)

    Article  Google Scholar 

  6. Dick, J. E. Breast cancer stem cells revealed. Proc. Natl Acad. Sci. USA 100, 3547–3549 (2003)

    Article  CAS  ADS  Google Scholar 

  7. Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005)

    Article  CAS  Google Scholar 

  8. Pocard, M., Tsukui, H., Salmon, R. J., Dutrillaux, B. & Poupon, M. F. Efficiency of orthotopic xenograft models for human colon cancers. In Vivo 10, 463–469 (1996)

    CAS  PubMed  Google Scholar 

  9. Ravi, R. et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64, 9105–9114 (2004)

    Article  CAS  Google Scholar 

  10. Golas, J. M. et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 65, 5358–5364 (2005)

    Article  CAS  Google Scholar 

  11. Sack, M. J. & Roberts, S. A. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn. Cytopathol. 16, 132–136 (1997)

    Article  CAS  Google Scholar 

  12. Ishida, H. et al. Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett. 207, 109–115 (2004)

    Article  CAS  Google Scholar 

  13. Liang, J. T. et al. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br. J. Surg. 91, 355–361 (2004)

    Article  CAS  Google Scholar 

  14. Porter, E. H. & Berry, R. J. The efficient design of transplantable tumour assays. Br. J. Cancer 17, 583–595 (1964)

    Article  Google Scholar 

  15. Wang, J. C., Doedens, M. & Dick, J. E. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89, 3919–3924 (1997)

    CAS  PubMed  Google Scholar 

  16. Al Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003)

    Article  CAS  ADS  Google Scholar 

  17. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004)

    Article  CAS  ADS  Google Scholar 

  18. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001)

    Article  CAS  ADS  Google Scholar 

  19. Marzesco, A. M. et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J. Cell Sci. 118, 2849–2858 (2005)

    Article  CAS  Google Scholar 

  20. Corbeil, D. et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J. Biol. Chem. 275, 5512–5520 (2000)

    Article  CAS  Google Scholar 

  21. Madlambayan, G. J. et al. Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. Exp. Hematol. 33, 1229–1239 (2005)

    Article  CAS  Google Scholar 

  22. Lapidot, T. et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645–648 (1994)

    Article  CAS  ADS  Google Scholar 

  23. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738–743 (2004)

    Article  CAS  Google Scholar 

  24. Al Hajj, M. & Clarke, M. F. Self-renewal and solid tumor stem cells. Oncogene 23, 7274–7282 (2004)

    Article  CAS  Google Scholar 

  25. Polyak, K. & Hahn, W. C. Roots and stems: stem cells in cancer. Nature Med. 12, 296–300 (2006)

    Article  CAS  Google Scholar 

  26. Al Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43–47 (2004)

    Article  CAS  Google Scholar 

Download references


We gratefully acknowledge assistance from F. Meng, H. Begley and C. Ash for tissue acquisition, D. Hedley for advice on establishment of the xenograft model, J Wang for assistance with manuscript preparation, and the Dick laboratory members, P. Dirks and D.Hill for comments on the manuscript. We also acknowledge K. So and the University Health Network Pathology Research Program for tissue sectioning and immunohistochemistry. This work was supported by: a clinician-scientist award (C.A.O’B.), and grants (J.E.D.) from the Canadian Institute of Health Research, as well as grants to J.E.D. from Genome Canada through the Ontario Genomics Institute, the Ontario Cancer Research Network with funds from the Province of Ontario, the Leukemia and Lymphoma Society, the National Cancer Institute of Canada with funds from the Canadian Cancer Society and the Terry Fox Foundation, and a Canada Research Chair (J.E.D.). Author Contributions C.A.O'B. planned the project, carried out experimental work, analysed data and prepared the manuscript. A.P. provided pathology analysis. S.G. provided clinical information and human tissues. J.E.D. planned the project, analysed data, and prepared the manuscript.

Author information

Authors and Affiliations


Corresponding author

Correspondence to John E. Dick.

Ethics declarations

Competing interests

Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary Figures

This file contains Supplementary Figures 1–4. Supplementary Figure 1: Unfractionated and CD133+ colon cancer cells initiate tumors when transplanted under the renal capsule of NOD/SCID mice. Supplementary Figure 2: Flow cytometric analysis of CD133 and ESA expression. Supplementary Figure 3: Histological examination following injection of CD133- colon cancer cells. Supplementary Figure 4: Analysis of purity following magnetic bead separation (PDF 1021 kb)

Supplementary Methods

This file contains additional details on the methods used in this study. (DOC 28 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

O’Brien, C., Pollett, A., Gallinger, S. et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing